Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
Category: #health  By Pankaj Singh  Date: 2019-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis’ trial of Entresto reveals potential beyond HFrEF treatment

Swiss pharma-company Novartis has reportedly revealed subgroup results from its global PARAGON-HF Phase III study. The trial involved a study of patients suffering from HFpEF (heart failure with preserved ejection fraction) or diastolic heart failure.

According to the analyses, Entresto shows considerably more promise than valsartan in reducing hospitalizations and fatalities from cardiovascular ailments, in certain subgroups. Greater advantage was observed in recently hospitalized HFpEF patients and female HFpEF patients.

Additionally, in a group analysis of PARADIGM-HF (HFrEF) and PARAGON-HF (HFpEF), treatment benefits were more prominent in patients with LVEF (left ventricular ejection fraction) less than 60%. Currently there is so approved treatment for HFpEF, which occurs disproportionately among women.

The new findings from the trial were revealed at the American Heart Association or AHA Scientific Session 2019. Publications of hospitalization analysis in the Journal of the American College of Cardiology and gender analysis in Circulation were also released simultaneously.

Entresto is presently an approved and vital treatment for HFrEF patients, generally involving less than or equal to 40% ejection fraction. This approval is based on its supremacy over enalapril, an ACE or angiotensin-converting enzyme. This superiority helps the drug reduce cardiovascular fatalities and hospitalizations due to heart failure, as revealed in the PARADIGM-HF trial.

Director of Noninvasive Cardiology at Brigham & Women’s Hospital, Harvard Medical School Professor and Executive Committee Co-Chair of PARAGON-HF, Scott Solomon, M.D., has apparently claimed that these new results demonstrate the benefits of Entresto in patients beyond HFrEF threshold. He further stated that these analyses would help gain a deeper understanding of HFpEF’s heterogeneous nature and unlock the potential advantage of Entresto for patients with unmet treatment needs.

PARAGON-HF Phase III complete results were presented at the 2019 ESC Congress. The study revealed a 13% relative decrease in the number of cardiovascular hospitalizations and deaths, narrowly missing statistical significance.
 

Source Credit: https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...